SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-267999
Filing Date
2022-10-25
Accepted
2022-10-25 08:01:03
Documents
15
Period of Report
2022-10-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d411848d8k.htm   iXBRL 8-K 45472
2 EX-99.1 d411848dex991.htm EX-99.1 24044
6 GRAPHIC g411848astellas.jpg GRAPHIC 10331
7 GRAPHIC g411848taysha.jpg GRAPHIC 11830
  Complete submission text file 0001193125-22-267999.txt   228621

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20221021.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20221021_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20221021_pre.xml EX-101.PRE 11705
9 EXTRACTED XBRL INSTANCE DOCUMENT d411848d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 221327218
SIC: 2836 Biological Products, (No Diagnostic Substances)